DA-JC4 - ≥96% , CAS No.2315504-40-4

CAS: 2315504-40-4 Cat. No.: D647378 Formule: C225H346N56O65 Poids moléculaire: 4875.49
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ ≥96%
Storage
Protected from light,Argon charged,Desiccated,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
Allemagne (EU)
USA*
Prix
Qté
5mg
D647378-5mg
Sur commande · 8–12 semaines
1 649,49€
Enter a quantity for the sizes you want to add.

Vue d’ensemble

DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways

In Vitro

DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus . DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission.

Form:Solid

IC50& Target:GLP-1/GIP

Spécifications

Spécifications et pureté
≥96%
Mécanismes biochimiques et physiologiques
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
Conditions de stockage de stockage
Protected from light,Argon charged,Desiccated,Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Type d'action
AGONIST
Pureté
≥96%
Noms et identifiants
Poids moléculaire
4875.49

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.